It has been selling on the old indication only for years, not the new indication.
I'm not against a buyout, I just want it to happen when we already have $3 billion+ in sales or more and a stock price at $90 or more. You see all the time now the so called unicorns are waiting much longer to do their IPOs so the early investors get a much higher percentage of the share gain and it isn't diluted by an IPO with everyone else.
In my mind we have a unicorn and the ones fortunate enough to be invested now, and indeed the ones invested before Reduce It trial results were announced in Sept 18, will make the most by GIA for the next few years, and then a company sell. Why do we want to share the wealth created by this drug with the current shareholders of a big Pharma?
In saying all of that, if I was a betting man I would bet we get purchased for between $50 - $60/share in the next 6 months. I just don't think this would be the best way for current shareholders to maximize their holdings.
JMO
Crikker
News 
Market Data 
Discover 
